Search results (1331)
« Back to PublicationsWindow of opportunity clinical trial designs to study cancer metabolism.
Aroldi F. and Lord SR., (2020), Br J Cancer, 122, 45 - 51
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
Sharma P. et al, (2019), Journal of Clinical Oncology, 37, 3484 - 3492
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin.
Lord SR. et al, (2019), British journal of cancer
Single-cell analysis of bone marrow-derived CD34+ cells from children with sickle cell disease and thalassemia.
Hua P. et al, (2019), Blood, 134, 2111 - 2115
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG. et al, (2019), Ann Oncol, 30, 2013 - 2014
Epstein-Barr Virus-Induced Cutaneous Diffuse Large B-Cell Lymphoma in a Patient With Angioimmunoblastic T-Cell Lymphoma.
Poon F. et al, (2019), Am J Dermatopathol, 41, 927 - 930
Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.
Suri A. et al, (2019), Clin Pharmacol Ther, 106, 1268 - 1279
Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
Findlay JM. et al, (2019), Eur Radiol, 29, 6717 - 6727
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.
O'Sullivan JM. et al, (2019), Blood, 134, 2107 - 2111
The T-cell architecture of pancreatic ductal adenocarcinoma
Sivakumar S. et al, (2019), CANCER RESEARCH, 79
Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study
McCain RS. et al, (2019), Cancer Causes & Control, 31, 1 - 11
Sugar thieves and addicts: nutrient subversion in JAK2 MPNs.
Brierley CK. and Psaila B., (2019), Blood, 134, 1778 - 1780
An International Multicentre Study of Consecutively Diagnosed Patients wSith ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice
Martinez-Calle N. et al, (2019), BLOOD, 134
Dose-Dependent Iron Chelating Effects of Eltrombopag on in Vitro Human Megakaryopoiesis
Liu Z-J. et al, (2019), BLOOD, 134
Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO
Goswami P. et al, (2019), BLOOD, 134
Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity
Djebbari F. et al, (2019), BLOOD, 134
Mouse Erythroid Cells Originate from a Megakaryocyte Precursor in Common Myeloid Progenitors
Heuston EF. et al, (2019), BLOOD, 134